STOCK TITAN
  1. Home
  2. News
  3. THRX

Theseus Pharmaceuticals Inc - THRX STOCK NEWS

Welcome to our dedicated news page for Theseus Pharmaceuticals (Ticker: THRX), a resource for investors and traders seeking the latest updates and insights on Theseus Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Theseus Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Theseus Pharmaceuticals's position in the market.

News
Theseus Pharmaceuticals Announces Closing of Tender Offer
Rhea-AI Summary
Theseus Pharmaceuticals, Inc. announces the successful completion of a tender offer by Concentra Biosciences, LLC, offering $4.05 per share in cash plus a contingent value right. The offer includes receiving 80% of net proceeds from certain programs and 50% of potential cost savings value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Concentra Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Theseus Pharmaceuticals
Rhea-AI Summary
Concentra Biosciences, LLC and its subsidiary entered into a merger agreement with Theseus Pharmaceuticals, Inc. (Nasdaq: THRX) for a cash acquisition price of $3.90 to $4.05 per share, plus a non-tradeable contingent value right (CVR). The tender offer to acquire outstanding shares expires on February 13, 2024. 16,604,692 shares have been tendered, representing 37.2% of outstanding shares. The acquisition is expected to close in February 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
none
-
News
Theseus Pharmaceuticals Enters into Agreement to Be Acquired by Concentra Biosciences for between $3.90 and $4.05 in Cash per Share Plus a Contingent Value Right
Rhea-AI Summary
Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) has entered into a definitive merger agreement with Concentra Biosciences, LLC, whereby Concentra will acquire Theseus for a price per share of Theseus common stock of between $3.90 and $4.05 in cash, plus one non-tradeable contingent value right. The acquisition is expected to close in February 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.81%
Tags
acquisition
News
Theseus Pharmaceuticals Confirms Receipt of Unsolicited Expression of Interest from Foresite Capital, LLC and OrbiMed Advisors LLC and Unsolicited Proposal from Concentra Biosciences LLC
Rhea-AI Summary
Theseus Pharmaceuticals, Inc. (THRX) received unsolicited acquisition proposals from Foresite Capital, LLC and OrbiMed Advisors LLC, as well as Tang Capital Partners, LP on behalf of Concentra Biosciences LLC. Foresite and OrbiMed intend to explore acquiring all outstanding shares in a going-private transaction, while Concentra Biosciences proposed to acquire all outstanding shares for $3.80 per share in cash, plus a contingent value right representing the right to receive 80% of the net proceeds from any license or disposition of Theseus' programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.97%
Tags
none
-
News
Theseus Pharmaceuticals Announces Process to Explore Strategic Alternatives
Rhea-AI Summary
Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) announced a strategic process to explore options for maximizing shareholder value, including a potential sale of assets, sale of the company, merger, or other strategic actions. The company also implemented a significant workforce reduction of approximately 72%, including the President of Research and Development. Theseus had cash, cash equivalents, and marketable securities of $225.4 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
50%
Tags
none
-
News
Theseus Pharmaceuticals to Participate in the Stifel 2023 Healthcare Conference
Rhea-AI Summary
NASDAQ: THRX - Theseus Pharmaceuticals, Inc. to Participate in Fireside Chat at Stifel 2023 Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.49%
Tags
conferences
News
Theseus Pharmaceuticals Announces Business Highlights and Reports Second Quarter 2023 Financial Results
Rhea-AI Summary
Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) reported business highlights and financial results for Q2 2023, including the advancement of lead candidate THE-349, a potential best-in-class fourth generation EGFR inhibitor. The company expects an IND submission for THE-349 in EGFR-mutant NSCLC in Q4 2023. Additionally, Theseus plans to nominate development candidates for BCR-ABL and next-generation KIT programs in H1 2024. The company also announced plans to explore the development of low dose THE-630 in mast cell-driven inflammatory indications. Theseus had $234.2 million of cash, cash equivalents, and marketable securities as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.51%
Tags
earnings
-
News
Theseus Pharmaceuticals to Discontinue Enrollment in Phase 1/2 Study and Terminate Development of THE-630 in Patients with GIST
Rhea-AI Summary
Theseus Pharmaceuticals discontinues development of THE-630 in GIST, prioritizes THE-349 for EGFR mutant lung cancer. $234 million in cash as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-72.06%
Tags
clinical trial
-
News
Theseus Pharmaceuticals to Participate in the Jefferies Healthcare Conference
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
conferences
News
Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.24%
Tags
clinical trial
Stock THRX logo
Theseus Pharmaceuticals Inc

Nasdaq:THRX

THRX Rankings

N/A Ranked by Market Cap
#4910 Ranked by Stock Gains
N/A Ranked by Dividends

THRX Stock Data

181.28M
14.26M
2.56%
84.08%
0.9%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Cambridge

About THRX

theseus pharmaceuticals is passionately committed to outsmarting cancer resistance. cancer is constantly mutating, allowing it to evade initially effective oncology treatments. theseus believes we can predict how cancer will change, enabling new therapies to stay ahead of future mutations and overcome the demonstrated burden of treatment resistance. led by a team of pioneers in the discovery and development of tyrosine kinase inhibitors (tkis), we are developing best-in-class, pan-variant kinase inhibitors, to shape the future of targeted oncology.